Noninvasive Needle‐Free Cancer Vaccine Cream Patch Based on Fluorinated Chitosan
Source abstract
Abstract
Abstract In recent years, cancer vaccines that intend to specifically initiate host immune responses against cancer have achieved some clinical success. Delivery of vaccines with traditional needles is usually associated with the risk of infection and poor patient compliance. The development of needle‐free vaccines may overcome these limitations. In this work, a needle‐free patch is designed for effective cancer vaccination using a fluorine chain‐modified cationic polymer, fluorinated chitosan (FCS), which is able to transdermatically deliver the antigen to antigen‐presenting cells in the skin. Specifically, a transdermal carrier, FCS, and model antigen ovalbumin (OVA) can self‐assemble into nanoparticles, which can reversibly open the tight junction‐associated proteins of epithelial cells and penetrate across the epidermis. The needle‐free cancer vaccine patch is fabricated by mixing FCS‐OVA nanoparticles with the US Food and Drug Administration‐approved immune adjuvant imiquimod (R837) in blank cream. Such a needle‐free cancer vaccine can generate robust immune responses to protect mice against ovalbumin‐expressing melanoma (B16‐OVA). Compared to traditional intradermal injection, needle‐free cancer vaccines achieved an even more efficient protection effect against B16‐OVA cancer cells. This work indicated that the novel needle‐free cancer vaccine may provide a compelling technology for simple and safe vaccination, which may help to increase vaccination coverage.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Advancements in Transdermal Drug Delivery · T-cell and B-cell Immunology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Functional Nano & Soft Materials (FUNSOM) Jiangsu Key Laboratory for Carbon‐Based Functional Materials and Devices Soochow University Suzhou 215123 China
Institute of Urology The Affiliated Luohu Hospital of Shenzhen University Shenzhen University Shenzhen 518000 China
Research Center for Macromolecules and Biomaterials National Institute for Materials Science Tsukuba Ibaraki 305‐0044 Japan
Funding
National Natural Science Foundation of China
References (50)
Show source-provided references
1. 10.1038/nature1067310.1038/nature10673 ↗
2. 10.1016/j.phrs.2020.10469110.1016/j.phrs.2020.104691 ↗
3. 10.1093/annonc/mdy49510.1093/annonc/mdy495 ↗
4. 10.1126/scitranslmed.aao593110.1126/scitranslmed.aao5931 ↗
5. 10.1158/2326-6066.CIR-19-054510.1158/2326-6066.CIR-19-0545 ↗
6. 10.1021/acsnano.9b0366010.1021/acsnano.9b03660 ↗
7. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
8. 10.1038/nm.340910.1038/nm.3409 ↗
9. 10.1038/3258810.1038/32588 ↗
10. 10.1021/acsnano.9b0597410.1021/acsnano.9b05974 ↗
11. 10.3389/fimmu.2018.0149910.3389/fimmu.2018.01499 ↗
12. 10.1146/annurev.immunol.17.1.59310.1146/annurev.immunol.17.1.593 ↗
13. 10.1038/4252310.1038/42523 ↗
14. 10.1016/j.drudis.2011.07.00410.1016/j.drudis.2011.07.004 ↗
15. 10.1371/journal.pone.000477310.1371/journal.pone.0004773 ↗
16. 10.1016/j.addr.2005.12.00310.1016/j.addr.2005.12.003 ↗
17. 10.1038/nri245510.1038/nri2455 ↗
18. 10.1586/14760584.7.8.120110.1586/14760584.7.8.1201 ↗
19. 10.1016/j.imlet.2007.01.00710.1016/j.imlet.2007.01.007 ↗
20. 10.1016/j.bbamem.2009.08.01510.1016/j.bbamem.2009.08.015 ↗
21. 10.1197/j.aem.2004.11.01910.1197/j.aem.2004.11.019 ↗
22. 10.4103/0250-474X.4032410.4103/0250-474X.40324 ↗
23. 10.1586/14760584.6.5.80910.1586/14760584.6.5.809 ↗
24. 10.1002/adma.20200212910.1002/adma.202002129 ↗
25. 10.5650/jos.62.65710.5650/jos.62.657 ↗
26. 10.1073/pnas.050117610210.1073/pnas.0501176102 ↗
27. 10.1016/j.addr.2008.03.00610.1016/j.addr.2008.03.006 ↗
28. 10.1016/S0264-410X(01)00225-010.1016/S0264-410X(01)00225-0 ↗
29. 10.1016/j.jconrel.2014.04.05210.1016/j.jconrel.2014.04.052 ↗
30. 10.3390/pharmaceutics704043810.3390/pharmaceutics7040438 ↗
31. Martirosyan A. · 2014
32. 10.1016/j.jconrel.2012.03.01710.1016/j.jconrel.2012.03.017 ↗
33. 10.1021/acsnano.9b0668910.1021/acsnano.9b06689 ↗
34. 10.1126/sciadv.aaz177410.1126/sciadv.aaz1774 ↗
35. 10.1016/j.nantod.2023.10183410.1016/j.nantod.2023.101834 ↗
36. 10.1126/sciadv.abq310410.1126/sciadv.abq3104 ↗
37. 10.1021/acsnano.2c0926610.1021/acsnano.2c09266 ↗
38. 10.1016/j.ijbiomac.2019.02.04710.1016/j.ijbiomac.2019.02.047 ↗
39. 10.3390/pharmaceutics1202015210.3390/pharmaceutics12020152 ↗
40. 10.1002/anie.20150862610.1002/anie.201508626 ↗
41. 10.1002/adma.20180222810.1002/adma.201802228 ↗
42. 10.1016/j.vetimm.2016.03.00510.1016/j.vetimm.2016.03.005 ↗
43. 10.1242/jcs.109.9.228710.1242/jcs.109.9.2287 ↗
44. 10.1083/jcb.138.1.18110.1083/jcb.138.1.181 ↗
45. 10.1016/j.scr.2015.02.00210.1016/j.scr.2015.02.002 ↗
46. 10.1016/j.bbamem.2007.10.01810.1016/j.bbamem.2007.10.018 ↗
47. 10.1083/jcb.123.6.177710.1083/jcb.123.6.1777 ↗
48. 10.1111/j.1749-6632.2009.04028.x10.1111/j.1749-6632.2009.04028.x ↗
49. 10.1042/bj2002040110.1042/bj20020401 ↗
50. 10.1046/j.0366-077X.2003.05628.x10.1046/j.0366-077X.2003.05628.x ↗